We are live on ! Find out more
GNOM icon

Global X Genomics & Biotechnology ETF

58 hedge funds and large institutions have $111M invested in Global X Genomics & Biotechnology ETF in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more capital invested

Capital invested by funds: $67.2M → $111M (+$43.6M)

4.99% more ownership

Funds ownership: 10.77%15.76% (+5%)

6% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 18

3% less funds holding

Funds holding: 6058 (-2)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

Holders
58
Holders Change
-2
Holders Change %
-3.33%
% of All Funds
0.98%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
17
Reduced
18
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Northwestern Mutual Wealth Management
1
Northwestern Mutual Wealth Management
Wisconsin
$54M +$56M +1,103,830 New
PAG
2
Private Advisor Group
New Jersey
$14.4M +$4.37M +86,271 +41%
PNC Financial Services Group
3
PNC Financial Services Group
Pennsylvania
$9.68M -$395K -7,799 -4%
Mirae Asset Global Investments
4
Mirae Asset Global Investments
South Korea
$7.24M -$577K -11,373 -7%
MIG
5
McGuire Investment Group
Rhode Island
$6.43M +$24.1K +475 +0.4%
OCM
6
One Capital Management
California
$5.04M +$707K +13,947 +16%
PGA
7
Portland Global Advisors
Maine
$2.43M +$2.52M +49,779 New
UBS Group
8
UBS Group
Switzerland
$2M -$3.38M -66,573 -62%
RJFSA
9
Raymond James Financial Services Advisors
Florida
$1.11M +$1.16M +22,791 New
EWM
10
Elmwood Wealth Management
California
$763K +$53.6K +1,057 +7%
MML Investors Services
11
MML Investors Services
Massachusetts
$754K -$560K -11,045 -42%
HighTower Advisors
12
HighTower Advisors
Illinois
$690K -$75.5K -1,489 -10%
MWAM
13
Manhattan West Asset Management
California
$621K +$130K +2,560 +25%
LPL Financial
14
LPL Financial
California
$612K -$263K -5,189 -29%
OAM
15
Oppenheimer Asset Management
New York
$567K +$19.2K +378 +3%
BS
16
Banco Santander
Spain
$533K -$179K -3,537 -24%
SWA
17
Sightline Wealth Advisors
Connecticut
$501K +$266K +5,247 +105%
IA
18
Insight Advisors
Pennsylvania
$486K +$21K +414 +6%
IWM
19
IHT Wealth Management
Illinois
$438K +$326K +6,437 +254%
Royal Bank of Canada
20
Royal Bank of Canada
Ontario, Canada
$371K +$145K +2,853 +60%
ACS
21
Archford Capital Strategies
Illinois
$289K +$6.54K +129 +2%
SWP
22
Stratos Wealth Partners
Ohio
$270K +$99.5K +1,962 +55%
Bank of America
23
Bank of America
North Carolina
$261K -$17.3K -342 -6%
AAS
24
Avantax Advisory Services
Texas
$258K +$268K +5,278 New
SAS
25
Stelac Advisory Services
New York
$156K +$67.2K +1,326 +71%

GNOM Hedge Fund Activity: Q2 2022 in Review

58 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Global X Genomics & Biotechnology ETF (GNOM) for Q2 2022, worth a combined $111M — up 65% from $67.2M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of GNOM and 7 opened new positions — a net loss of 2 holders — while 18 trimmed existing stakes and 17 added.

The largest buyer was Northwestern Mutual Wealth Management, opening a new position worth an estimated $56M. The largest seller was UBS Group, cutting an estimated $3.38M.

  • 58 institutional investors held Global X Genomics & Biotechnology ETF (GNOM) as of Q2 2022, down from 60 in Q1 2022.
  • Funds reported $111M of Global X Genomics & Biotechnology ETF stock for Q2 2022, up 65% quarter-over-quarter.
  • 7 funds opened new Global X Genomics & Biotechnology ETF positions in Q2 2022 and 9 closed out, a net change of -2 holders.
  • The largest Global X Genomics & Biotechnology ETF buyer in Q2 2022 was Northwestern Mutual Wealth Management, an estimated $56M added.
  • The largest Global X Genomics & Biotechnology ETF seller in Q2 2022 was UBS Group, an estimated $3.38M sold.

Based on aggregated 13F filings for Q2 2022.